When asked about Cures-related hiring, CDER Director says to her knowledge, no funding has been received yet.
Additional funding through the 21st Century Cures Act for the US FDA to work on several mandates intended to help bring new drugs to market faster does not appear to have arrived yet.
Center for Drug Evaluation and Research Director Janet Woodcock said April 24 that funding through the legislation continues to navigate...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
